Jessica Tassan
Stock Analyst at Piper Sandler
(0.94)
# 3,539
Out of 4,754 analysts
66
Total ratings
24.07%
Success rate
-11.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jessica Tassan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: Overweight | $13 → $12 | $8.95 | +34.15% | 6 | Feb 27, 2025 | |
| EVH Evolent Health | Reiterates: Overweight | $17 → $16 | $8.76 | +82.75% | 3 | Feb 21, 2025 | |
| HCAT Health Catalyst | Maintains: Overweight | $12 → $8 | $4.42 | +81.20% | 11 | Feb 11, 2025 | |
| PINC Premier | Maintains: Neutral | $21 → $19 | $17.87 | +6.32% | 5 | Feb 5, 2025 | |
| CI The Cigna Group | Reiterates: Overweight | $394 → $348 | $312.21 | +11.46% | 3 | Feb 3, 2025 | |
| PHR Phreesia | Reiterates: Overweight | $31 → $33 | $24.93 | +32.37% | 5 | Jan 29, 2025 | |
| HUM Humana | Maintains: Neutral | $270 → $288 | $262.96 | +9.52% | 3 | Jan 15, 2025 | |
| UNH UnitedHealth Group | Maintains: Overweight | $605 → $600 | $476.86 | +25.82% | 5 | Jan 2, 2025 | |
| CVS CVS Health | Maintains: Overweight | $72 → $64 | $64.98 | -1.50% | 4 | Nov 25, 2024 | |
| OSCR Oscar Health | Reiterates: Overweight | $28 | $15.08 | +85.68% | 4 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 → $10 | $15.43 | -35.19% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $6.97 | +115.36% | 4 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $21 → $23 | $67.17 | -65.76% | 3 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $66 → $70 | $37.37 | +87.32% | 4 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $70 | $8.37 | +736.32% | 2 | Feb 27, 2023 |
Teladoc Health
Feb 27, 2025
Maintains: Overweight
Price Target: $13 → $12
Current: $8.95
Upside: +34.15%
Evolent Health
Feb 21, 2025
Reiterates: Overweight
Price Target: $17 → $16
Current: $8.76
Upside: +82.75%
Health Catalyst
Feb 11, 2025
Maintains: Overweight
Price Target: $12 → $8
Current: $4.42
Upside: +81.20%
Premier
Feb 5, 2025
Maintains: Neutral
Price Target: $21 → $19
Current: $17.87
Upside: +6.32%
The Cigna Group
Feb 3, 2025
Reiterates: Overweight
Price Target: $394 → $348
Current: $312.21
Upside: +11.46%
Phreesia
Jan 29, 2025
Reiterates: Overweight
Price Target: $31 → $33
Current: $24.93
Upside: +32.37%
Humana
Jan 15, 2025
Maintains: Neutral
Price Target: $270 → $288
Current: $262.96
Upside: +9.52%
UnitedHealth Group
Jan 2, 2025
Maintains: Overweight
Price Target: $605 → $600
Current: $476.86
Upside: +25.82%
CVS Health
Nov 25, 2024
Maintains: Overweight
Price Target: $72 → $64
Current: $64.98
Upside: -1.50%
Oscar Health
Sep 10, 2024
Reiterates: Overweight
Price Target: $28
Current: $15.08
Upside: +85.68%
Aug 6, 2024
Reiterates: Overweight
Price Target: $8 → $10
Current: $15.43
Upside: -35.19%
Jan 9, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $6.97
Upside: +115.36%
Nov 10, 2023
Maintains: Neutral
Price Target: $21 → $23
Current: $67.17
Upside: -65.76%
Aug 2, 2023
Downgrades: Neutral
Price Target: $66 → $70
Current: $37.37
Upside: +87.32%
Feb 27, 2023
Downgrades: Neutral
Price Target: $100 → $70
Current: $8.37
Upside: +736.32%